1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. đť•Ź Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. đť•Ź Posts
Discussion
1. Investment Snapshot
2. Valuation
Discussion
Symbol
BRBM
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
—
Shares Offered
29.93M
Shares Outstanding Pre-IPO
39.52M
39.52M
—
75.7%
Implied Upside vs Midpoint
Description
The Company is a clinical stage biopharmaceutical company focused on developing treatments for scarring (fibrosis, i.e., the overproduction and insufficient breakdown (or remodeling) of ECM proteins, predominantly collagen and fibronectin, within an organ) and related skin disorders; certain autoimmune diseases (diseases consisting of immune responses of an organism against its own cells and tissues); and organ fibrosis. We hold the exclusive, worldwide, non-perpetual pharmaceutical licenses from the University of British Columbia (“UBC”) for two scientific technologies, FS1/FS2 and AI-001. Based on preclinical studies and clinical trials we have conducted to date, we believe these technologies hold the potential for significant medical breakthroughs in the treatment of certain debilitating conditions/disorders in need of novel, better solutions. FS1, known as kynurenine, and FS2, known as kynurenic acid, are respectively first- and second-generation small molecule candidates used as monotherapy for anti-scarring. FS1 and FS2 can each be made by conventional chemical methods but are also produced within the body. FS1 is produced within the body through the breakdown of tryptophan, an essential amino acid (a building block for all proteins) needed for production and maintenance of the body’s proteins, muscles, enzymes, and neurotransmitters. Enzymes are proteins that facilitate the catalytic conversion of a compound (or protein) into a new, chemically different compound. For example, some enzymes break compounds into smaller parts, others build larger compounds and others modify compounds in ways that render them chemically reactive (on) or non-reactive (off). FS2 is produced within the body through the breakdown of FS1 and, unlike FS1, remains unchanged prior to excretion from the body. We believe FS2 works in treatment by preventing and promoting the breakdown of scars on the molecular level. AI-001 is a first-generation candidate autoimmune therapy that comprises a one-time injection of antigen producing cells (“APCs”) and daily administration of FS2 topically or systemically. Based on pre-clinical and gold standard animal model studies it appears that AI-001 may work by resetting the body’s immune system. Key strategic donors and government bodies, including the Canadian Institutes of Health Research (“CIHR”), and the Natural Sciences and Engineering Research Council of Canada (“NSERC”), which is responsible for managing research programs/initiatives and government funding within the health sciences and life sciences in Canada, initially funded the FS1/FS2 and AI-001 technologies we license from UBC. The CIHR and NSERC are the Canadian counterparts of the U.S. National Institutes of Health (“NIH”) which is responsible for managing research programs/initiatives and government funding within the health sciences and life sciences in the U.S. --- Our principal executive offices are located at 130 Kingscross Drive, King City, Ontario, Canada L7B 1E6, and our telephone number is 905-833-3414. Our website address is https://birchbiomed.com.